QUICK ANSWER
Semaglutide has demonstrated cardiovascular safety and efficacy in large clinical trials, but requires proper medical screening before starting. The most common side effects are gastrointestinal (nausea, vomiting, diarrhea) and are dose-dependent — manageable with slow titration. Semaglutide is contraindicated in patients with a history of medullary thyroid carcinoma, pancreatitis, MEN2, or pregnancy.
Semaglutide is having a cultural moment that few medications in history have matched. With dramatic clinical trial results and widespread media coverage, it's become the most prescribed weight loss medication in the US. But with popularity comes risk — not just the risk of the medication itself, but the risk of receiving it without proper medical evaluation.
This guide covers what the research actually shows about semaglutide's safety, who should and shouldn't use it, and what proper medical oversight looks like in Fort Myers.
What Does the Research Say?
Semaglutide (the active ingredient in Ozempic and Wegovy) has undergone extensive clinical trials. The STEP program — a series of large randomized controlled trials — enrolled thousands of participants and followed them for 68+ weeks. Key safety findings:
- Cardiovascular safety: The SUSTAIN-6 trial showed a significant reduction in major adverse cardiovascular events in high-risk patients. Semaglutide is now FDA-approved for cardiovascular risk reduction in addition to weight management.
- Gastrointestinal effects: The most common side effects are nausea (44%), vomiting (24%), diarrhea (30%), and constipation (24%). These are dose-dependent and typically improve after the titration phase (weeks 4–16). A slow titration protocol significantly reduces their severity.
- Pancreatitis: A rare but serious concern. Patients with a history of pancreatitis should not use semaglutide. The absolute risk is low but requires screening.
- Thyroid C-cell tumors: Observed in rodent studies at extremely high doses; not confirmed in humans but represents a contraindication for those with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Who Should NOT Use Semaglutide?
Semaglutide is contraindicated for:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN2)
- History of pancreatitis
- Pregnancy or breastfeeding
- Type 1 diabetes
- Severe gastroparesis
- Severe kidney or liver disease
This is why a medical evaluation before starting semaglutide is not optional — it's essential. Signing up for a medication program online without a physician review is genuinely dangerous for patients with these contraindications.
What Does "Medically Supervised" Actually Mean?
At Solace Wellness Aesthetics, medical weight loss under Dr. Flávio Jamur's supervision includes:
- Complete medical history review and contraindication screening
- Baseline metabolic labs
- Personalized starting dose based on your profile
- Slow titration protocol to minimize GI side effects
- Regular follow-up visits to monitor progress and adjust dosing
- Muscle preservation guidance (protein intake targets)
- Integration with other modalities as appropriate
This is meaningfully different from online prescription services that issue prescriptions after a 5-minute questionnaire with no lab work and no follow-up. The medication is the same — the difference is whether someone qualified is monitoring your response to it.
Semaglutide vs. Tirzepatide: Which Is Safer?
Tirzepatide (Mounjaro/Zepbound) has a similar safety profile to semaglutide with generally comparable GI side effects. SURMOUNT-1 trial data showed tirzepatide produced greater average weight loss (20.9% of body weight vs. 14.9% for semaglutide). The choice between them should be made by your prescribing provider based on your metabolic profile and insurance coverage.
Questions to Ask Your Provider
Before starting any GLP-1 program in Fort Myers, ask:
- Will I have baseline labs before starting?
- What is your titration protocol?
- How will side effects be managed?
- Who do I contact if I have a reaction?
- What are the contraindications you screened me for?
The safety and efficacy data referenced in this article draw from the STEP 1-4 clinical trial program (Wilding et al., New England Journal of Medicine, 2021) and the SUSTAIN-6 cardiovascular outcomes trial (Marso et al., NEJM, 2016). These are peer-reviewed, published clinical trials with thousands of participants.
STEP 1 Trial: Wilding et al., NEJM 2021 →This article is for educational purposes only. Always consult a licensed provider before starting any treatment.